MovDisordV3, PascalFrancis, Corpus, bibRecord, 002F83

Current status of selegiline as a neuroprotective agent in Parkinson's disease

Identifieur interne : 002F83 ( PascalFrancis/Corpus ); précédent : 002F82; suivant : 002F84

Current status of selegiline as a neuroprotective agent in Parkinson's disease

Auteurs : C. W. Olanow ; C. Mytilineou ; W. Tatton

Source :

Movement disorders [ 0885-3185 ] ; 1998.

RBID : Pascal:98-0322505

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Sélégiline, Antiparkinsonien, Chimiothérapie, Traitement, Homme, Neuroprotecteur.

English descriptors

KwdEn :
- Antiparkinson agent, Chemotherapy, Human, Neuroprotective agent, Parkinson disease, Selegiline, Treatment.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 13`
A06				`@3 SUP1`
A08	`01`	`1`	`ENG`	`@1 Current status of selegiline as a neuroprotective agent in Parkinson's disease`
A11	`01`	`1`		`@1 OLANOW (C. W.)`
A11	`02`	`1`		`@1 MYTILINEOU (C.)`
A11	`03`	`1`		`@1 TATTON (W.)`
A12	`01`	`1`		`@1 FAHN (Stanley) @9 préf.`
A12	`02`	`1`		`@1 BURKE (Robert E.) @9 préf.`
A12	`03`	`1`		`@1 MAYEUX (Richard) @9 préf.`
A12	`04`	`1`		`@1 PRZEDBORSKI (Serge) @9 préf.`
A14	`01`			`@1 Department of Neurology, Mount Sinai School of Medicine @2 New York, NY @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut.`
A15	`01`			`@1 The Neurological Institute @2 New York, NY @3 USA @Z 1 aut.`
A15	`02`			`@1 Department of Neurology, Columbia University @2 New York, NY @3 USA @Z 2 aut.`
A15	`03`			`@1 Columbia University, Neurology Department @2 New York, NY @3 USA @Z 4 aut.`
A15	`04`			`@1 The Gertrude H. Sergievsky Center @2 New York, NY @3 USA @Z 3 aut.`
A18	`01`	`1`		`@1 The Parkinson's Disease Foundation @3 INC @9 patr.`
A20				`@1 55-58`
A21				`@1 1998`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000075576800100`
A44				`@0 0000 @1 © 1998 INIST-CNRS. All rights reserved.`
A45				`@0 46 ref.`
A47	`01`	`1`		`@0 98-0322505`
A60				`@1 P @2 C`
A61				`@0 A`
A64		`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C02	`01`	`X`		`@0 002B02B06`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Sélégiline @2 NK @2 FR @5 04`
C03	`02`	`X`	`ENG`	`@0 Selegiline @2 NK @2 FR @5 04`
C03	`02`	`X`	`SPA`	`@0 Selegilina @2 NK @2 FR @5 04`
C03	`03`	`X`	`FRE`	`@0 Antiparkinsonien @5 05`
C03	`03`	`X`	`ENG`	`@0 Antiparkinson agent @5 05`
C03	`03`	`X`	`SPA`	`@0 Antiparkinsoniano @5 05`
C03	`04`	`X`	`FRE`	`@0 Chimiothérapie @5 16`
C03	`04`	`X`	`ENG`	`@0 Chemotherapy @5 16`
C03	`04`	`X`	`SPA`	`@0 Quimioterapia @5 16`
C03	`05`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`05`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`05`	`X`	`GER`	`@0 Aufbereiten @5 17`
C03	`05`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`06`	`X`	`FRE`	`@0 Homme @5 20`
C03	`06`	`X`	`ENG`	`@0 Human @5 20`
C03	`06`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`07`	`X`	`FRE`	`@0 Neuroprotecteur @5 23`
C03	`07`	`X`	`ENG`	`@0 Neuroprotective agent @5 23`
C03	`07`	`X`	`SPA`	`@0 Neuroprotector @5 23`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
N21				`@1 215`

A30	`01`	`1`	`ENG`	`@1 Frontiers in Parkinson's Disease. Symposium @3 New York City USA @4 1997-05-31`

Format Inist (serveur)

NO :	PASCAL 98-0322505 INIST
ET :	Current status of selegiline as a neuroprotective agent in Parkinson's disease
AU :	OLANOW (C. W.); MYTILINEOU (C.); TATTON (W.); FAHN (Stanley); BURKE (Robert E.); MAYEUX (Richard); PRZEDBORSKI (Serge)
AF :	Department of Neurology, Mount Sinai School of Medicine/New York, NY/Etats-Unis (1 aut., 2 aut., 3 aut.); The Neurological Institute/New York, NY/Etats-Unis (1 aut.); Department of Neurology, Columbia University/New York, NY/Etats-Unis (2 aut.); Columbia University, Neurology Department/New York, NY/Etats-Unis (4 aut.); The Gertrude H. Sergievsky Center/New York, NY/Etats-Unis (3 aut.)
DT :	Publication en série; Congrès; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1998; Vol. 13; No. SUP1; Pp. 55-58; Bibl. 46 ref.
LA :	Anglais
CC :	002B02B06
FD :	Parkinson maladie; Sélégiline; Antiparkinsonien; Chimiothérapie; Traitement; Homme; Neuroprotecteur
FG :	Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative
ED :	Parkinson disease; Selegiline; Antiparkinson agent; Chemotherapy; Treatment; Human; Neuroprotective agent
EG :	Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease
GD :	Aufbereiten
SD :	Parkinson enfermedad; Selegilina; Antiparkinsoniano; Quimioterapia; Tratamiento; Hombre; Neuroprotector
LO :	INIST-20953.354000075576800100
ID :	98-0322505

Links to Exploration step

Pascal:98-0322505

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Current status of selegiline as a neuroprotective agent in Parkinson's disease</title>
<author><name sortKey="Olanow, C W" sort="Olanow, C W" uniqKey="Olanow C" first="C. W." last="Olanow">C. W. Olanow</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Mount Sinai School of Medicine</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mytilineou, C" sort="Mytilineou, C" uniqKey="Mytilineou C" first="C." last="Mytilineou">C. Mytilineou</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Mount Sinai School of Medicine</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tatton, W" sort="Tatton, W" uniqKey="Tatton W" first="W." last="Tatton">W. Tatton</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Mount Sinai School of Medicine</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">98-0322505</idno>
<date when="1998">1998</date>
<idno type="stanalyst">PASCAL 98-0322505 INIST</idno>
<idno type="RBID">Pascal:98-0322505</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002F83</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Current status of selegiline as a neuroprotective agent in Parkinson's disease</title>
<author><name sortKey="Olanow, C W" sort="Olanow, C W" uniqKey="Olanow C" first="C. W." last="Olanow">C. W. Olanow</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Mount Sinai School of Medicine</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mytilineou, C" sort="Mytilineou, C" uniqKey="Mytilineou C" first="C." last="Mytilineou">C. Mytilineou</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Mount Sinai School of Medicine</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tatton, W" sort="Tatton, W" uniqKey="Tatton W" first="W." last="Tatton">W. Tatton</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Mount Sinai School of Medicine</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1998">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Human</term>
<term>Neuroprotective agent</term>
<term>Parkinson disease</term>
<term>Selegiline</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Sélégiline</term>
<term>Antiparkinsonien</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Homme</term>
<term>Neuroprotecteur</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>13</s2>
</fA05>
<fA06><s3>SUP1</s3>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Current status of selegiline as a neuroprotective agent in Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>OLANOW (C. W.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MYTILINEOU (C.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>TATTON (W.)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>FAHN (Stanley)</s1>
<s9>préf.</s9>
</fA12>
<fA12 i1="02" i2="1"><s1>BURKE (Robert E.)</s1>
<s9>préf.</s9>
</fA12>
<fA12 i1="03" i2="1"><s1>MAYEUX (Richard)</s1>
<s9>préf.</s9>
</fA12>
<fA12 i1="04" i2="1"><s1>PRZEDBORSKI (Serge)</s1>
<s9>préf.</s9>
</fA12>
<fA14 i1="01"><s1>Department of Neurology, Mount Sinai School of Medicine</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>The Neurological Institute</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA15 i1="02"><s1>Department of Neurology, Columbia University</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA15>
<fA15 i1="03"><s1>Columbia University, Neurology Department</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA15>
<fA15 i1="04"><s1>The Gertrude H. Sergievsky Center</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA15>
<fA18 i1="01" i2="1"><s1>The Parkinson's Disease Foundation</s1>
<s3>INC</s3>
<s9>patr.</s9>
</fA18>
<fA20><s1>55-58</s1>
</fA20>
<fA21><s1>1998</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000075576800100</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1998 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>46 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>98-0322505</s0>
</fA47>
<fA60><s1>P</s1>
<s2>C</s2>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Sélégiline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Selegiline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Selegilina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>16</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>16</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>16</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="05" i2="X" l="GER"><s0>Aufbereiten</s0>
<s5>17</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Neuroprotecteur</s0>
<s5>23</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Neuroprotective agent</s0>
<s5>23</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Neuroprotector</s0>
<s5>23</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fN21><s1>215</s1>
</fN21>
</pA>
<pR><fA30 i1="01" i2="1" l="ENG"><s1>Frontiers in Parkinson's Disease. Symposium</s1>
<s3>New York City USA</s3>
<s4>1997-05-31</s4>
</fA30>
</pR>
</standard>
<server><NO>PASCAL 98-0322505 INIST</NO>
<ET>Current status of selegiline as a neuroprotective agent in Parkinson's disease</ET>
<AU>OLANOW (C. W.); MYTILINEOU (C.); TATTON (W.); FAHN (Stanley); BURKE (Robert E.); MAYEUX (Richard); PRZEDBORSKI (Serge)</AU>
<AF>Department of Neurology, Mount Sinai School of Medicine/New York, NY/Etats-Unis (1 aut., 2 aut., 3 aut.); The Neurological Institute/New York, NY/Etats-Unis (1 aut.); Department of Neurology, Columbia University/New York, NY/Etats-Unis (2 aut.); Columbia University, Neurology Department/New York, NY/Etats-Unis (4 aut.); The Gertrude H. Sergievsky Center/New York, NY/Etats-Unis (3 aut.)</AF>
<DT>Publication en série; Congrès; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1998; Vol. 13; No. SUP1; Pp. 55-58; Bibl. 46 ref.</SO>
<LA>Anglais</LA>
<CC>002B02B06</CC>
<FD>Parkinson maladie; Sélégiline; Antiparkinsonien; Chimiothérapie; Traitement; Homme; Neuroprotecteur</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative</FG>
<ED>Parkinson disease; Selegiline; Antiparkinson agent; Chemotherapy; Treatment; Human; Neuroprotective agent</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease</EG>
<GD>Aufbereiten</GD>
<SD>Parkinson enfermedad; Selegilina; Antiparkinsoniano; Quimioterapia; Tratamiento; Hombre; Neuroprotector</SD>
<LO>INIST-20953.354000075576800100</LO>
<ID>98-0322505</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F83 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002F83 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:98-0322505
   |texte=   Current status of selegiline as a neuroprotective agent in Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Current status of selegiline as a neuroprotective agent in Parkinson's disease

Current status of selegiline as a neuroprotective agent in Parkinson's disease

Source :

Descripteurs français

English descriptors

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri